Organs on a chip

submitted by: nsf

Organs on a chip systems could transform the medical drug pipeline as we know it. Biomedical engineer Ali Khademhosseini explains how he and his team at MIT are engineering tissues outside of the human body and connecting different "organs" to solve some pressing challenges.

Breakthrough Therapies for Idiopathic Pulmonary Fibrosis

submitted by: mcgheek

Timothy P.M. Whelan, M.D., Medical Director of the Lung Transplant Program at the Medical University of South Carolina, discusses promising clinical trial results of new agents (pirfenidone, nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF). To date, only supportive care and transplant (for eligible patients) have been available to IPF patients, but these new trial results could lead to FDA approval of the first drugs for IPF.

PharmGenEd™ Principles and Concepts of Pharmacogenomics

submitted by: KuoOffice

The presentation is divided into several sections as outlined by the powerpoint slide. In this module we will include the basic concepts of pharmacogenomics, ethical, legal, social issues, and a brief introduction of the PharmGenEd program.

Novel cell-based and materials science approach to target Glioblastoma brain cancer tumors

submitted by: nsf

Stefan Bossmann and Deryl Troyer at Kansas State University are developing a novel materials treatment method for persons with brain cancer that uses a type of white blood cell to deliver anticancer drugs to particularly virulent brain tumors.

Science Behind the News: Allergies

submitted by: nsf

Seasonal Allergies affect more than 40 million Americans each year. Plant biologist Dr. Kristina Stinson of Harvard University explains how allergies affect the body, and why warmer weather could lead to longer, more severe allergy seasons. "Science Behind the News" is produced in partnership with NBC Learn.

Provided by the National Science Foundation & NBC Learn

Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study

Aim The aim of this randomized placebo-controlled clinical trial was to evaluate the effects of Lactobacillus reuteri-containing probiotic lozenges as an adjunct to scaling and root planing (SRP). Material and Methods Thirty chronic periodontitis patients were recruited and monitored clinically and microbiologically at baseline, 3, 6, 9 and 12 weeks after therapy. All patients received one-stage full-mouth disinfection and randomly assigned over a test (SRP + probiotic, n = 15) or...
Authors: Wim Teughels, Andac Durukan, Onur Ozcelik, Martine Pauwels, Marc Quirynen, Mehmet Cenk Haytac